Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epatoguna is a dietary supplement developed by Guna S.p.a. designed to support liver health and facilitate the repair of damaged liver tissue. The core component is a lyophilized porcine liver extract (Neorland), which contains bioactive peptides and exosomes that exert cytoprotective and proliferative effects on hepatocytes. This extract is intended to stimulate the natural regenerative processes of the liver, particularly following hepatocellular injury such as that caused by acetaminophen (paracetamol) toxicity. The formulation is further enhanced with choline bitartrate, which aids in normal lipid metabolism and prevents fat accumulation in the liver, and green tea extract (Camellia sinensis), which provides antioxidant protection against oxidative stress. It is marketed as a nutraceutical for the management of liver metabolic homeostasis and recovery from toxic or inflammatory insults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Epatoguna.